Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Redx Rises Out Of Administration With R&D Refocus

Executive Summary

After a tough summer, the UK firm has exited insolvency with new management and programs in cancer and fibrosis, having decided to shut down its anti-infectives business.

You may also be interested in...



UK's Redx Rises On Stock Sale

A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.

Redx Raises Funds And Remains Independent

Redx's takeover talks with a consortium led by controversial biotech veteran Sam Waksal, who was jailed for five years over his role in the ImClone stock scandal in 2003, have been terminated but the UK biotech has received a financial lifeline from Redmile and Sofinnova.

Redx Cashes In Cancer Program With Jazz Pact

Shares in the UK biotech tripled to a 52-week high after it announced the sale of its pan-RAF inhibitor program to Jazz that could eventually be worth around $200m.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel